Immunoendocrine associations in adrenal glands
Authors:
I. Šterzl; P. Hrdá
Authors‘ workplace:
Endokrinologický ústav Praha, ředitel doc. MUDr. Vojtěch Hainer, CSc.
Published in:
Vnitř Lék 2010; 56(12): 1286-1291
Category:
Celebration
Overview
Immune and endocrine systems are basic regulatory mechanisms of organism and, including the nervous system, maintain the organism’s homeostasis. The main immune system representatives are mononuclear cells, T‑ and B‑ cells and their products, in the endocrine system the main representatives are cells of the glands with inner secretion and their products. One of the most important glands for maintaining homeostasis are adrenal glands. It has been proven that either cells of the immune system, either endocrine cells can, although in trace amounts, produce mutually mediators of both systems (hormones, cytokines). Disorders in one system can lead to pathological symptoms in the other system. Also here represent adrenals an important model.
Key words:
adrenal glands – Addison’s disease – lymphocytes – cytokines – glucocorticoids – autoantibodies – autoantigens
Sources
1. Addison T. On the constitutional and local effects of disease of the suprarenal capsules. In a collection of the published writings of the late Thomas Addison, MD, physician to Guy’s Hospital, London. London: New Sydenham Society 1986 (reprinted in Medical Classics 1937, 2, 244– 293).
2. Schmidt MB. Eine biglandulate Eokankung (Nebennieren ind Schildruse) bei Morbus Addisonii. Verh Dtsch Ges Pathol 1926; 21: 212– 221.
3. Carpenter C, Solomon N, Silverberg S et al. Schmidt’s syndrome (thyroid and adrenal insufficiency). A review of the literature and a report of 15 new cases including 10 instances of co‑ existend diabetes mellitus. Medicien (Baltimore) 1964; 43: 153– 180.
4. Neufeld M, Blizzard RM. Polyglandular autoimmune disease. In: Pinchera A, Doniach D, Fenzi GF et al (eds). Symposium on Autoimmune Aspects of Endocrine Disordes. New York: Acadenic Press 1980: 357– 365.
5. Šterzl I. Přehledná imunoendokrinologie. Praha: Maxdorf 2006: 39– 41.
6. Šterzl I. Přehledná imunoendokrinologie. Praha: Maxdorf 2006: 48– 50.
7. Šterzl I, Hampl R, Sterzl J et al. 7Beta‑OH‑ DHEA counteracts dexamethasone induced suppression of primary immune response in murine spleenocytes. J Steroid Biochem Mol Biol 1999; 71: 133– 137.
8. Coco G, Dal Pra C, Presotto F et al. Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 2006; 91: 1637– 1645.
9. Betterle C, Dal Pra C, Mantero F et al. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002; 23: 327– 364.
10. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol 2009; 161: 11– 20.
12. Erichsen MM, Løvås K, Skinningsrud B et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94: 4882– 4890.
12. Brozzetti A, Marzotti S, Tortoioli C et al. Cytotoxic T-lymphocyte antigen‑ 4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta‑analysis of European studies. Eur J Endocrinol 2010; 162: 361– 369.
13. Betterle C, Dal Pra C, Mantero F et al. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002; 23: 327– 364.
14. Bratland E, Skinningsrud B, Undlien DE et al. T cell responses to steroid cytochrome P450 21‑ hydroxylase in patients with autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab 2009; 94: 5117– 5124.
15. Winqvist O, Karlsson FA, Kämpe O. 21‑ Hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 1992; 339: 1559– 1562.
16. Bednarek J, Furmaniak J, Wedlock N et al. Steroid 21‑ hydroxylase is a major autoantigen involved in adult onset autoimmune Addison’s disease. FEBS Lett 1992; 309: 51– 55.
17. Baumann‑Antczak A, Wedlock N, Bednarek J et al. Autoimmune Addison’s disease and 21‑ hydroxylase. Lancet 1992; 340: 429– 430.
18. Song YH, Connor EL, Muir A et al. Autoantibody epitope mapping of the 21‑ hydroxylase antigen in autoimmune Addison’s disease. J Clin Endocrinol Metab 1994; 78: 1108– 1112.
19. Peterson P, Uibo R, Peränen J et al. Immunoprecipitation of steroidogenic enzyme autoantigens with autoimmune polyglandular syndrome type I (APS I) sera; further evidence for independent humoral immunity to P450c17 and P450c21. Clin Exp Immunol 1997; 107: 335– 340.
20. Betterle C, Coco G, Zanchetta R. Adrenal cortex autoantibodies in subjects with normal adrenal function. Best Pract Res Clin Endocrinol Metab 2005; 19: 85– 99.
21. Scherbaum WA, Berg PA. Development of adrenocortical failure in non‑Addisonian patients with antibodies to adrenal cortex. A clinical follow‑up study. Clin Endocrinol (Oxf) 1982; 16: 345– 352.
22. Ketchum CH, Riley WJ, Maclaren NK. Adrenal dysfunction in asymptomatic patients with adrenocortical autoantibodies. J Clin Endocrinol Metab 1984; 58: 1166– 1170.
23. Laureti S, De Bellis A, Muccitelli VI et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison’s disease. J Clin Endocrinol Metab 1998; 83: 3507– 3511.
24. De Bellis AA, Falorni A, Laureti S et al. Time course of 21‑ hydroxylase antibodies and long‑term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J Clin Endocrinol Metab 2001; 86: 675– 678.
25. Šterzl I, Hrdá P, Matucha P et al. Polyglandulární aktivace autoimunity jako projev subklinických endokrinopatií. Čas Lék Čes 2007; 146: 256– 261.
26. Weetman AP. Autoimmunity to steroid‑ producing cells and familial polyendocrine autoimmunity. Baillieres Clin Endocrinol Metab 1995; 9: 157– 174.
27. Chen S, Sawicka J, Betterle C et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison’s disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81: 1871– 1876.
28. Betterle C, Volpato M, Greggio AN et al. Type 2 polyglandular autoimmune disease (Schmidt’s syndrome). J Pediatr Endocrinol Metab 1996; 9 (Suppl 1): 113– 123.
29. Bottazo GF, Mirakian R, Drexhage HA. Adrenalitis, oophoritis and autoimmune polyglandular disease. In: Rich RR, Fleisher TA, Schwarz DB et al (eds). Clinical immunology, principles and practice. St Louis: Mosby 1996: 1523– 1536.
30. Dal Pra C, Chen S, Furmaniak J et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison’s disease. Eur J Endocrinol 2003; 148: 565– 570.
31. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997; 18: 107– 134.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2010 Issue 12
Most read in this issue
- Extremly low SHBG level in consequence of Pro156Leu SHBG polymorphism – case reports of two women with polycystic ovary syndrome
- Pulmonary Langerhans cell histiocytosis – evaluation of the disease activity and treatment response using PET‑CT (SUVmax Pulmo/ SUVmax Hepar index). Description of own experience and literature review
- Activity of the hypothalamic – pituitary – adrenal axis in patients with rheumatoid arthritis
- HIV lipodystrophy